Zentalis Pharmaceuticals, Inc.
ZNTL
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$142M
▲ +17.4% YoY
Op. Margin
–
ROIC
-52.94%
▼ -3.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$134M
▲ +26.8% YoY
Op. Cash Flow (TTM)
-$134M
▲ +26.7% YoY
Net Debt
-$192M
Net Cash Position
Cash & Equiv.
$229M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ZNTL
Held by ETFs
ZNTL is in 5 US ETFs. The largest of them, with ZNTL's weight in each:
Zentalis Pharmaceuticals (ZNTL) in three numbers
Questions about Zentalis Pharmaceuticals
Is Zentalis Pharmaceuticals a high-quality business?
Zentalis Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$192M, and its weakest is return on capital at -52.9%. The Quality tab shows every check against its target.
Does Zentalis Pharmaceuticals (ZNTL) pay a dividend?
No. Zentalis Pharmaceuticals (ZNTL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 7.5% buyback yield. The Dividends tab shows its cash returns.
Source: 10-Q filed 4 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ZNTL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ZNTL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.